Keyphrases
Advanced Breast Cancer
17%
Alternative Schedule
14%
Anti-EGFR
29%
Bone-only Metastasis
29%
Breast Cancer
25%
Cancer Treatment
21%
Circulating Tumor DNA (ctDNA)
81%
Clinical Outcomes
14%
Clinical Trials
29%
Confidence Interval
19%
COVID-19 Pandemic
14%
Cyclin-dependent Kinase 4 (CDK4)
31%
DNA Analysis
16%
DNA Assay
17%
DNA Characterization
14%
Early-stage Triple-negative Breast Cancer
16%
Endocrine Therapy
17%
ER +
17%
Estrogen Receptor 1 (ESR1)
17%
Genetic Modification
19%
Genome Complexity
14%
Geriatric Population
21%
HER2-negative Metastatic Breast Cancer
16%
HER2-positive
24%
High Risk
22%
Hormone Receptor-positive
24%
Human Epidermal Growth Factor Receptor 2 (HER2)
18%
Invasive Lobular Carcinoma
14%
Letrozole
19%
Metastatic Breast Cancer
68%
NCCN Guidelines
14%
Neoadjuvant
17%
Neoadjuvant Chemotherapy
21%
Older Adults
47%
Older Patients
18%
Oncogenic Pathways
21%
Overall Survival
28%
Palbociclib
45%
Pathological Complete Response
29%
Phase II Trial
16%
PIK3CA
20%
Progression-free Survival
30%
Resistance Mechanisms
16%
Resistant Clones
14%
Serum Thymidine Kinase 1
14%
Single Institution
17%
Social Support
14%
Triple-negative Breast Cancer
34%
Tumor Subtype
14%
Young Patients
21%
Medicine and Dentistry
Anti-Epidermal Growth Factor Receptor
29%
Biological Marker
18%
Bone Metastasis
11%
BRCA Mutation
14%
Breast Cancer
50%
Cancer Therapy
10%
Cancer Treatment
21%
Carboplatin
14%
Circulating Tumor Cell
14%
Circulating Tumor DNA
82%
Clinical Trial
43%
Colorectal Carcinoma
16%
COVID-19
14%
Cyclin-Dependent Kinase 4
14%
DNA Determination
18%
Docetaxel
14%
Drug Dose Reduction
8%
Epidermal Growth Factor Receptor
22%
Exome Sequencing
9%
Fibroblast Growth Factor Receptor 3
8%
Gene Mutation
14%
Geriatric Assessment
15%
Geriatrics
31%
Hormone Receptor
8%
Hormone Therapy
17%
Immunity
14%
Intermittent Fasting
14%
Lobular Carcinoma
14%
Loneliness
14%
Malignant Neoplasm
40%
Metastatic Breast Cancer
100%
Metastatic Carcinoma
29%
Neoadjuvant Chemotherapy
22%
Neoplasm
40%
Odds Ratio
12%
Oncology
14%
Overall Survival
31%
Palbociclib
30%
Partial Breast Irradiation
14%
Pembrolizumab
14%
Phase II Trials
16%
Prognostic Factor
14%
Progression Free Survival
33%
Receptor
14%
Recurrent Disease
13%
Social Isolation
14%
Social Support
14%
Targeted Therapy
14%
Thymidine Kinase 1
14%
Triple Negative Breast Cancer
43%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
5%
Biological Marker
18%
Bone Metastasis
7%
Breast Cancer
36%
Carboplatin
14%
Chemotherapy
32%
Circulating Tumor DNA
50%
Clinical Trial
34%
Colorectal Carcinoma
13%
Cyclin Dependent Kinase 4
14%
Disease Exacerbation
16%
Disease Free Survival
8%
Docetaxel
14%
Endocrine Therapy
35%
Epidermal Growth Factor Receptor
31%
Fibroblast Growth Factor Receptor 3
7%
Hormone Receptor
26%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
14%
Immunotherapy
6%
Letrozole
19%
Malignant Neoplasm
8%
Metastatic Breast Cancer
69%
Monotherapy
8%
Neoplasm
28%
Neutropenia
8%
Overall Survival
24%
Palbociclib
45%
Pembrolizumab
14%
Phase II Trials
16%
Progression Free Survival
45%
Recurrent Disease
7%
RNA-Sequencing
5%
Solid Malignant Neoplasm
14%
Thymidine Kinase 1
14%
Trastuzumab
14%
Triple Negative Breast Cancer
43%